Abstract
British Journal of Cancer (2002) 87, 1480–1480. doi:10.1038/sj.bjc.6600652 www.bjcancer.com
Correction to: British Journal of Cancer 2001; 85 (Suppl 2): 1–5. doi:10.1054/bjoc.2001.1981
An error has been noted within Figure 1. The chemotherapy regimen shown in the ECOG/SWOG/CALGB INT-0101 study is incorrect and should be six cycles of CAF (cyclophosphamide/adriamycin/5-fluorouracil) and not six cycles of CMF (cyclophosphamide/methotrexate/5-fluorouracil), as presented. The corrected version of the figure is shown here.
Figure 1.
Clinical trials designs for studies involved in the evaluation of goserelin as adjuvant treatment in early breast cancer in pre-/perimenopausal patients.